Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Genentech believes Avastin effective for some

Genentech believes Avastin effective for some

22nd April 2009

Genentech is disappointed that its phase III trial of Avastin did not meet primary endpoints but believes the product still has the potential to be effective for some patients, it has said.

The clinical study ? known as NSABP C-08 ? tested the drug for its ability to treat colon cancer sufferers immediately after surgery.

It was found not to lower the risk of the disease returning during the first trial of the medication in early cancer, but the results do not alter indications that it can be beneficial for those with advanced forms of the illness.

Dr Hal Barron is the senior vice-president of development and chief medical officer at Genentech.

He commented: “We remain fully committed to the ongoing Avastin adjuvant programs in early-stage colon, breast and lung cancers.”

Last month, Genentech became a wholly-owned member of the Roche group after the latter successfully completed its acquisition of the firm.

Subject to appraisal rights, all remaining public shareholders were set to receive $95 (64.92 pounds) per unit for their shares.

As of March 26th, Genentech’s common stock was no longer traded on the New York Stock Exchange.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.